LEO PHARMA A/S: Financial statements 2022
CVR: 56759514
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
LEO PHARMA A/S (CVR 56759514) has filed annual accounts for 2022. In 2022, the company reported revenue of EUR 10,641,000,000 and a net result of EUR -4,110,000,000 compared with DKK -4,868,000,000 the year before. That is an increase of 6.9% compared with the year before. The profit margin was -38.6%. Equity in the 2022 report amounted to EUR 1,946,000,000. The solvency ratio was 8.5%. The company had 5,252 employees in the financial year.
- Revenue
- EUR 10,641,000,000
- Gross Profit
- EUR 5,985,000,000
- Profit/Loss
- EUR -4,110,000,000
- Equity
- EUR 1,946,000,000
- Total Assets
- EUR 22,932,000,000
- Employees
- 5,252
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 10.6 mia. EUR | 6 mia. EUR | -4.1 mia. EUR | 1.9 mia. EUR | 5252 |
| 2021 | 10 mia. | 6 mia. | -4.9 mia. | 5.5 mia. | - |
| 2020 | 10.1 mia. | 6.8 mia. | -951 mio. | 6.9 mia. | - |
| 2019 | 10.8 mia. | 7.5 mia. | -1.3 mia. | 8.1 mia. | - |
| 2018 | 10.4 mia. | 7.4 mia. | 1.3 mia. | 9.5 mia. | - |
Official annual report
Keep an eye on LEO PHARMA A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of September 15, 2022, Philip Harald Eickhoff is registered as director of LEO PHARMA A/S.
As of September 15, 2022, Anders Kronborg has stepped down as director of LEO PHARMA A/S.
As of August 29, 2022, Paul Olivier Marie Navarre has joined the board of directors of LEO PHARMA A/S.
As of July 1, 2022, Klaus Legau has joined the board of directors of LEO PHARMA A/S.
As of July 1, 2022, Louisa Channouf Jacobsen has left the board of directors of LEO PHARMA A/S.
As of June 24, 2022, Lena Elisabeth Svanberg has joined the board of directors of LEO PHARMA A/S.
As of April 1, 2022, Anders Kronborg is registered as director of LEO PHARMA A/S.
As of April 1, 2022, Christophe Dominique Luc Charles Bourdon is registered as adm. dir. of LEO PHARMA A/S.
As of March 31, 2022, Anders Kronborg has stepped down as adm. dir. of LEO PHARMA A/S.
LEO PHARMA A/S has published its annual report for 2021. Revenue came to DKK 9,957,000,000, and the net result was DKK -4,868,000,000.
About LEO PHARMA A/S
LEO PHARMA A/S is a Danish company of the type Aktieselskab based in Ballerup, founded in 1962. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named LØVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB. The management consists of Christophe Dominique Luc Charles Bourdon and Philip Harald Eickhoff. The board consists of Jesper Brandgaard (chair), Paul Olivier Marie Navarre, Peter Helt Jacobsen Haahr and Aino Anna Liisa Hurme. The company is owned by LEO Holding A/S and Cidron Savanna 4 SARL. The company has 1,047 employees (2026). In 2025, the company reported revenue of DKK 13,499,000,000 and a net result of DKK 2,489,000,000 compared with DKK -1,776,000,000 the year before. Equity in the 2025 report amounted to DKK 5,262,000,000.